Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 5/20 | 0.88 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.78 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.78 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.78 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.78 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.78 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.78 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.78 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.78 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.78 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.78 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.78 |
| ▸ | PIM1 | P11309 | 1/20 | 0.76 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.76 |
| ▸ | BRAF | P15056 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7051381 | 0.98 | MAP2K1 (0.96) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL4856675 | 0.97 | MAP2K1 (0.94) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL29482205 | 0.94 | MAP2K1 (1.00) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL4858053 | 0.94 | MAP2K1 (1.00) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL4856753 | 0.91 | MAP2K1 (0.83) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL4861634 | 0.91 | MAP2K1 (0.83) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL30022418 | 0.90 | MAP2K1 (0.85) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL22030445 | 0.90 | MAP2K1 (0.85) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL14067393 | 0.90 | MAP2K1 (0.82) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 | |
| SCHEMBL4861807 | 0.89 | MAP2K1 (0.81) | MAP2K1MAP2K2HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7411001-B2 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2008-08-12 | — | — | US | claimed |
| US-6972298-B2 | Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor | WARNER-LAMBERT COMPANY (US) | 2005-12-06 | — | — | US | claimed |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2005-08-11 | — | — | US | claimed |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2004-03-18 | — | — | US | claimed |
| CN-1446197-A | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER LAMBERT CO (US) | 2003-10-01 | — | — | CN | claimed |
| US-20030055095-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | BARAGI VIJAYKUMAR M (US) | 2003-03-20 | — | — | US | claimed |
| EP-1262176-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | WARNER-LAMBERT COMPANY (US) | 2002-12-04 | — | — | EP | claimed |
| EP-1301472-B1 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER LAMBERT CO (US) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012135779-A1 | COMBINATIONS OF AKT AND MEK INHIBITOR COMPOUNDS, AND METHODS OF USE | GENENTECH, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| EP-2497825-A1 | Novel method for rapid and efficient generation of neuroectoderm cells and peripheral neurons from pluripotent stem cells | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011029802-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| WO-2009036082-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-7411001-B2 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-6972298-B2 | Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor | WARNER-LAMBERT COMPANY (US) | 2005-12-06 | — | — | US | disclosed |
| US-6960614-B2 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2005-08-11 | — | — | US | disclosed |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2004-03-18 | — | — | US | disclosed |
| US-20030055095-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | BARAGI VIJAYKUMAR M (US) | 2003-03-20 | — | — | US | disclosed |
| EP-1262176-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | WARNER-LAMBERT COMPANY (US) | 2002-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | CYP4X1, CYP2A7, CYP4B1 | MAP2K1 4341/4885MAP2K2 4268/4885HDAC3 903/4885 |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | CYP4X1, ALOX5, HAAO | MAP2K1 4312/4885MAP2K2 4025/4885HDAC3 1650/4885 |
| US-20030055095-A1 | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor | MMP8, SERPINB1, CXCR2 | MAP2K1 105/4885MAP2K2 89/4885HDAC3 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.